Misplaced Pages

ASC41

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

ASC41 is a thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta. It is developed for non-alcoholic fatty liver disease. In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.

References

  1. Fröhlich, Eleonore; Wahl, Richard (4 August 2022). "Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease". Metabolites. 12 (8): 718. doi:10.3390/metabo12080718. ISSN 2218-1989. PMC 9414490. PMID 36005590.
  2. "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache". Fierce Biotech. 3 January 2023. Retrieved 2 December 2023.
  3. "Viking Therapeutics accuses competitor of pilfering proprietary information". Chemical & Engineering News. January 9, 2023. Viking infers that ASC41 is Ascletis's version of—if not the same compound as—VK2809
Categories:
ASC41 Add topic